Skip to Content

Long-Term Patient-Reported Outcomes Data from the JAVELIN Bladder 100 Trial in Patients with Advanced Urothelial Carcinoma

The JAVELIN Bladder 100 trial has previously shown a survival benefit with switch maintenance avelumab anti-PD-1 therapy in patients who had a response or stable disease after platinum-based chemotherapy. In this MEDtalk, Dr. Petros Grivas presents the long-term data presented at ASCO GU 2024, which confirmed that the significant prolongation in overall and progression-free survival was achieved with a significant preservation to the patient’s quality of life.

Petros Grivas

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top